UK cystic fibrosis network to accelerate new therapeutics
LifeArc and Cystic Fibrosis Trust are jointly investing £15 million to establish a network of research hubs that will accelerate the discovery of novel diagnostics and therapeutics for lung infections.
The Translational Innovation Hub Network for Lung Health and Infection will consist of four Innovation Hubs, based in Cambridge, Liverpool, London and Manchester.
It will provide a national infrastructure that encourages collaboration and supports better understanding and management of chronic respiratory infections, pulmonary exacerbations and inflammation.
Dr Catherine Kettleborough, Head of Chronic Respiratory Infections at LifeArc said: “Even with the development of new treatments like Kaftrio, people with cystic fibrosis still face many challenges which impact their quality of life and life expectancy. The Innovation Hub Network is a unique approach to addressing some of these problems, using shared knowledge, partnerships and investment to accelerate new tests and treatments for people living with CF.”
Researchers in Cambridge will use the latest innovations in machine learning and app technology, to try to predict pulmonary exacerbations and allow for earlier interventions.
Other Innovation Hubs will focus on developing novel therapeutics, including phage therapy, to transform the way lung infections are managed.
The network will bring together world-leading experts from different fields of knowledge to provide a training ground for the next generation of scientists and clinicians.
Dr Lucy Allen, Director of Research and Healthcare Data at the Cystic Fibrosis Trust, commented: “We’re thrilled to be partnering with LifeArc and expanding our Innovation Hub programme. Those with the condition are particularly susceptible to lung infections, meaning they often have to spend time in hospital having IV antibiotic treatments and this has a huge impact on all areas of their life. These new Innovation Hubs will help transform our understanding and lead the way to new ways to test and treat lung infections.”
Diana Spencer, Senior Digital Content Editor, DDW
